



## Clinical trial results:

### Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer.

#### Summary

EudraCT number	2016-004632-38
Trial protocol	SK
Global end of trial date	09 May 2019

#### Results information

Result version number	v1 (current)
This version publication date	04 September 2021
First version publication date	04 September 2021

#### Trial information

##### Trial identification

Sponsor protocol code	GCTSK005
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03403777
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Národný onkologický ústav
Sponsor organisation address	Klenova 1, Bratislava, Slovakia, 83310
Public contact	Oddelenie klinických skúšaní, Národný onkologický ústav, 00421 259378592, daniela.svetlovska@nou.sk
Scientific contact	Oddelenie klinických skúšaní, Národný onkologický ústav, 00421 259378592, daniela.svetlovska@nou.sk

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	28 February 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	28 February 2019
Global end of trial reached?	Yes
Global end of trial date	09 May 2019
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

To determine the efficacy (as measured by 12-week progression-free survival) of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors.

Protection of trial subjects:

All the procedures performed in study involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Background therapy:

NA

Evidence for comparator:

NA

Actual start date of recruitment	13 November 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Slovakia: 8
Worldwide total number of subjects	8
EEA total number of subjects	8

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	8
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

Enrollment started from 13.11.2017 to 23.1.2019, 8 patients were enrolled.

### Pre-assignment

Screening details:

Relapsed/refractory testicular germ cell cancer.

### Pre-assignment period milestones

Number of subjects started	8
Number of subjects completed	8

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Avelumab
-----------	----------

Arm description:

Subjects intravenously received 10 mg/kg of Avelumab every two weeks until progression or unacceptable toxicity or other reason.

Arm type	Experimental
Investigational medicinal product name	Avelumab
Investigational medicinal product code	MSB0010718C
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

10mg/kg every 2 weeks

<b>Number of subjects in period 1</b>	Avelumab
Started	8
Completed	8

## Baseline characteristics

### Reporting groups

Reporting group title	Overall Study (overall period)
-----------------------	--------------------------------

Reporting group description: -

Reporting group values	Overall Study (overall period)	Total	
Number of subjects	8	8	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	8	8	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical Units: Subjects			
Female	0	0	
Male	8	8	

## End points

### End points reporting groups

Reporting group title	Avelumab
Reporting group description:	
Subjects intravenously received 10 mg/kg of Avelumab every two weeks until progression or unacceptable toxicity or other reason.	
Subject analysis set title	Overall study
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Single arm trial	

### Primary: 12-week progression-free survival rate

End point title	12-week progression-free survival rate
End point description:	
Twelve-week PFS in the first 8 patients was 0%, therefore the study was terminated because of futility.	
End point type	Primary
End point timeframe:	
12-week progression free survival rate was defined as number of living patients without progression after 12-week of start of study treatment.	

End point values	Avelumab	Overall study		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	8	8		
Units: number of patients	0	0		

### Statistical analyses

Statistical analysis title	description statistics
Comparison groups	Avelumab v Overall study
Number of subjects included in analysis	16
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	< 5
Method	Chi-squared

Notes:

[1] -

8 patients were analysed, subject in analyses 16 is number doubling automatically by the system

### Secondary: Response rate

End point title	Response rate
End point description:	
None of the enrolled patients had partial or complete response to the study treatment.	
End point type	Secondary

End point timeframe:

Objective response rate is defined as sum of complete and partial responses. It is defined from start of the treatment until progression of disease or start of new anticancer treatment.

End point values	Avelumab			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: number of patients	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: overall survival

End point title	overall survival
End point description: Median OS was 2.7 months, 95% CI (1.0 – 3.3).	
End point type	Secondary
End point timeframe: Overall survival was calculated from the beginning of treatment until death from any cause on intention-to-treat basis.	

End point values	Avelumab			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: month				
median (confidence interval 95%)	2.7 (1.0 to 3.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression-free survival

End point title	Progression-free survival
End point description: Median PFS was 0.9 months, 95%CI (0.5 – 1.9)	
End point type	Secondary
End point timeframe: Progression-free survival was calculated from the beginning of the treatment until progression or death from disease-specific cause on intention-to-treat basis.	

<b>End point values</b>	Avelumab			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: month				
median (confidence interval 95%)	0.9 (0.5 to 1.9)			

### Statistical analyses

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were recorded from start of study treatment until 28 days after study treatment discontinuation.

Adverse event reporting additional description:

7 patients experienced any AE grade 1-3, none of the patients experienced grade 4-5 AE. Also none of the patients experienced SAE.

Secondary end point was grade 3/4 toxicity, grade 3 toxicity experienced 5 patients, grade 4 none of the patients.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
Dictionary version	4.0

### Reporting groups

Reporting group title	Avelumab
-----------------------	----------

Reporting group description:

7 patients from 8 experienced adverse events from grade 1 to grade 3. None of patients experienced grade 4 or 5 adverse events. None of the patients experienced SAE.

Serious adverse events	Avelumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)		
number of deaths (all causes)	7		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Avelumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 8 (87.50%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumor pain	Additional description: Grade 3 tumor pain experienced 3 patients. None patient experienced grade 4. Only grade 3/4 are reported.		
subjects affected / exposed	3 / 8 (37.50%)		
occurrences (all)	3		
Cachexia	Additional description: Grade 3 cachexia experienced 1 patient. None patient experienced grade 4. Only grade 3/4 are reported.		
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		

Investigations			
Platelet count decreased	Additional description: Grade 3 platelet count decreased experienced 1 patient. None patient experienced grade 4. Only grade 3/4 are reported.		
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anemia	Additional description: Grade 3 anemia experienced 1 patient. None patient experienced grade 4. Only grade 3/4 are reported.		
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
General disorders and administration site conditions			
Fatigue	Additional description: Grade 3 fatigue experienced 1 patient. None patient experienced grade 4. Only grade 3/4 are reported.		
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Dyspnea	Additional description: Grade 3 dyspnea experienced 1 patient. None patient experienced grade 4. Only grade 3/4 are reported.		
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Renal and urinary disorders			
Urinary retention	Additional description: 1 patient experienced urinary retention grade 3. None patient experienced grade 4. Only grade 3/4 are reported.		
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Hypoalbuminemia	Additional description: Grade 3 hypoalbuminemia experienced 1 patient. None patient experienced grade 4. Only grade 3/4 are reported.		
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/31152292>